NanoVibronix, Inc. announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The pilot phase of the study is the first component of the broader study. As previously announced on November 28, 2023, the company signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (RCT) study of UroShield to further advance clinical evidence of the efficacy of UroShield.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7202 USD | -2.28% | -3.50% | -37.37% |
1st Jan change | Capi. | |
---|---|---|
-37.37% | 2.05M | |
-5.10% | 184B | |
-3.71% | 103B | |
-5.02% | 67.59B | |
+15.23% | 46.93B | |
-9.98% | 43.87B | |
+8.28% | 41.2B | |
+17.17% | 30.47B | |
+13.59% | 24.16B | |
-7.99% | 23.57B |
- Stock Market
- Equities
- NAOV Stock
- News NanoVibronix, Inc.
- NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan